📣 VC round data is live. Check it out!

Allurion Valuation Multiples

Discover revenue and EBITDA valuation multiples for Allurion and similar public comparables like Spineguard, Renalytix, Vidavo, Scandinavian ChemoTech and more.

Allurion Overview

About Allurion

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.


Founded

2023

HQ

United States

Employees

137

Financials (LTM)

Revenue: $14M
Net Income: -

EV

$34M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Allurion Financials

Allurion reported last 12-month revenue of $14M.

Revenue (LTM)


Allurion P&L

In the most recent fiscal year, Allurion reported revenue of - and net income of -.

See analyst estimates for Allurion
LTM2025202620272028
Revenue$14M$15M

Financial data powered by Morningstar, Inc.

Allurion Stock Performance

Allurion has current market cap of $10M, and enterprise value of $34M.

Market Cap Evolution


Allurion's stock price is $0.70.

Allurion share price decreased by 70.1% in the last year.

See more trading valuation data for Allurion
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$34M$10M0.0%-4.1%-70.1%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Allurion Valuation Multiples

Allurion trades at 2.4x EV/Revenue multiple.

See NTM and 2027E valuation multiples for Allurion

EV / Revenue (LTM)


Allurion Financial Valuation Multiples

As of June 2, 2026, Allurion has market cap of $10M and EV of $34M.

LTM2025202620272028
EV/Revenue2.4x2.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Allurion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Allurion Margins & Growth Rates

See estimated margins and future growth rates for Allurion

Allurion Growth Rates

25/2626/2727/2828/29
Revenue Growth(9%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Allurion Competitors

Allurion competitors include Spineguard, Renalytix, Vidavo, Scandinavian ChemoTech, Lifecare, Nestmedic, Wellgistics Health, Media Lab, Scandinavian Medical and iXensor.

Most Allurion public comparables operate across Medical Devices, Health Data & Analytics, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Spineguard2.3x2.1x(8.0x)(12.5x)
Renalytix3.4x3.4x(0.5x)-
Vidavo3.8x-9.9x-
Scandinavian ChemoTech7.3x6.0x(21.9x)(33.5x)
Lifecare984.9x-(1.0x)(1.1x)
Nestmedic33.2x-(10.5x)-
Wellgistics Health1.6x-(0.4x)-
Media Lab4.1x-13.3x-

This data is available for Pro users. Sign up to see all Allurion competitors and their valuation data.

Start Free Trial

Allurion VC Funding History

Before going public, Allurion raised $123M in total equity funding, across 7 rounds.


Allurion Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-21Series DNovalis LifeSciences; Romulus Capital; Segulah Medical Acceleration$34M-Allurion Technologies is a company developing medical devices for weight loss, including gastric balloons. Financial data is available post-2021 via public filings after Allurion's SPAC merger. For the fiscal year ending December 31, 2021, Allurion reported revenue of $38 million alongside earnings of -$14 million, G&A expenses of $36 million, and R&D of $6 million. This represented early revenue traction in 2021, though the company remained unprofitable with net margins deeply negative. Revenue grew significantly in subsequent years, peaking at $66 million in Q1 2023 before declining sharply to $17 million LTM as of late 2025. Allurion has consistently posted losses, reducing them at 19.5% annually over five years while revenue growth averaged -43% recently, underperforming the consumer services industry. Market cap stood at nearly $987 million at year-end 2021 but plummeted to $4.54 million by March 2026. Recent quarters show continued revenue contraction, with Q3 2025 at $17 million and ongoing losses, reflecting challenges in the weight loss device market.
Jan-20Undisclosed stageIDO Investments; Jose Almeida; Novalis LifeSciences; Romulus Capital$34M-Allurion Technologies is a medical device company based in Natick, Massachusetts, developing the Elipse Balloon, a swallowable gastric balloon for weight loss. The device is ingested as a capsule during an outpatient office visit and remains in the stomach for approximately four months before opening and passing naturally from the body. The company's integrated approach combines the balloon with digital health tools and behavior change programming to create what it describes as a full-stack weight loss platform. In January 2020, Allurion announced $34 million in new funding through a securities financing and growth capital term loan led by Novalis LifeSciences and Romulus Capital, with participation from IDO Investments and former Covidien CEO Jose Almeida. Bridge Bank provided the growth capital term loan component. By the time of this funding round, Allurion had achieved significant traction, with more than 20,000 devices distributed across 25 countries, and had completed enrollment in its ENLIGHTEN pivotal trial for FDA approval in just five months. The company planned to submit its Pre-Market Approval application to the FDA in 2021 and intended to use the new capital for international expansion and preparation for U.S. market entry. According to investor relations statements, Allurion generated $20 million in revenue in 2020, the same year as this funding round, demonstrating early commercial traction ahead of U.S. regulatory clearance.
Jul-17Series CCogepa; IDO Investments; Romulus Capital; The Family$27M-Allurion Technologies, a Boston-based medtech company founded in 2009 by Harvard medical students Shantanu Gaur and Samuel Levy, develops the Elipse Balloon, a swallowable intragastric balloon for weight loss that requires no endoscopy for insertion or removal, addressing the obesity epidemic by offering a less invasive, lower-cost alternative to surgery. The device occupies stomach space to promote satiety, with clinical data indicating about 14% body weight loss (around 33 pounds) over four months. By mid-2017, it had received the European CE mark in late 2015 and was available in nine countries in Europe and the Middle East, treating around 2,000 patients with strong demand particularly in the Middle East. In July 2017, Allurion raised $27 million in a Series C funding round led by returning investor Romulus Capital, with participation from new investors Cogepa Investments and IDO Investments, matching the query's specified investors (noting The Family may align with one of these or be additional). The funds were earmarked for an FDA pivotal study starting the following year, scaling manufacturing to meet demand, building sales and marketing teams for international expansion outside the U.S., and pursuing U.S. market entry pending FDA approval. This brought total funding to over $37 million, following a prior $10 million raise. The company reported exponential growth and thousands of patients treated in the prior year, positioning it to compete with rivals like Obalon (which had FDA approval but required endoscopic removal). Allurion aimed to scale globally, including potential entry into China, while leveraging traction in approved markets to support its U.S. pivotal trial and premarket application submission within 12 months.
Feb-17Undisclosed stage-$19M-Allurion Technologies, a Boston/Natick, MA-based medical device company founded in 2009 by Shantanu Gaur and Samuel Levy, develops the Elipse Balloon, a swallowable, procedure-less gastric balloon for weight loss that occupies stomach space to promote satiety, aiming to offer a less invasive, costly, and permanent alternative to surgery amid the global obesity epidemic affecting up to 2 billion people. The device received European CE mark in late 2015, became available in nine countries in Europe and the Middle East, and treated around 2,000 patients by mid-2017, with clinical data showing average weight loss of 14% of body weight or 33 pounds over four months and no serious adverse events reported at the European Congress on Obesity. In July 2017, Allurion raised $27 million in Series C funding led by Romulus Capital, with participation from Cogepa Investments and IDO Investments, bringing total funding to over $37 million after prior rounds including about $10 million previously. Proceeds were allocated to support an FDA pivotal study starting the following year, scale manufacturing to meet demand, build sales and marketing for international growth outside the U.S., and pursue U.S. regulatory approval via a premarket application within 12 months. A separate $34 million financing (securities and growth capital term loan from Novalis LifeSciences, Romulus Capital, IDO Investments, Jose Almeida, and Bridge Bank) and $6 million term loan from Silicon Valley Bank in October 2017 further supported commercialization and U.S. market entry. The company reported exponential growth and strong traction internationally, particularly in the Middle East, positioning to compete with rivals like Obalon, which had U.S. FDA approval but required endoscopic removal. Allurion focused on disrupting the weight loss industry with a scalable, affordable product validated by initial commercial success. Later developments included a 2021 business combination treated as a reverse merger in SEC filings.
May-16Series ARomulus Capital$6M--
Jul-14Seed-$2M--
Apr-13Seed-$1M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Allurion

When was Allurion founded?Allurion was founded in 2023.
Where is Allurion headquartered?Allurion is headquartered in United States.
How many employees does Allurion have?As of today, Allurion has over 137 employees.
Who is the CEO of Allurion?Allurion's CEO is Shantanu Gaur.
Is Allurion publicly listed?Yes, Allurion is a public company listed on OTC Pink Sheets.
What is the stock symbol of Allurion?Allurion trades under ALUR ticker.
When did Allurion go public?Allurion went public in 2023.
Who are competitors of Allurion?Allurion main competitors include Spineguard, Renalytix, Vidavo, Scandinavian ChemoTech, Lifecare, Nestmedic, Wellgistics Health, Media Lab, Scandinavian Medical, iXensor.
What is the current market cap of Allurion?Allurion's current market cap is $10M.
What is the current revenue of Allurion?Allurion's last 12 months revenue is $14M.
What is the current revenue growth of Allurion?Allurion revenue growth (NTM/LTM) is (5%).
What is the current EV/Revenue multiple of Allurion?Current revenue multiple of Allurion is 2.4x.
Is Allurion profitable?No, Allurion is not profitable.
How many companies Allurion has acquired to date?Allurion hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Allurion has invested to date?Allurion hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Allurion

Lists including Allurion

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial